Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18651603,flow rate,"Chromatographic separation was carried on an Acquity UPLC BEH C(18) column (50 x 2.1 mm, i.d., 1.7 microm) with an isocratic mobile phase consisting of acetonitrile and containing 0.1% formic acid (75:25, v/v) at flow rate of 0.4 mL/min, and total run time was within 1 min.","Simultaneous determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using ultra-performance liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651603/),[ml] / [min],0.4,28,DB06267,Udenafil
,18651603,total run time,"Chromatographic separation was carried on an Acquity UPLC BEH C(18) column (50 x 2.1 mm, i.d., 1.7 microm) with an isocratic mobile phase consisting of acetonitrile and containing 0.1% formic acid (75:25, v/v) at flow rate of 0.4 mL/min, and total run time was within 1 min.","Simultaneous determination of udenafil and its active metabolite, DA-8164, in human plasma and urine using ultra-performance liquid chromatography-tandem mass spectrometry: application to a pharmacokinetic study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18651603/),min,1,29,DB06267,Udenafil
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],283,2102,DB06267,Udenafil
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],349,2103,DB06267,Udenafil
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],98.0,2104,DB06267,Udenafil
,15926192,total areas under the plasma concentration-time curve from time zero to time infinity (AUC),"After a 1 min intravenous administration of DA-8159 at a dose of 30 mg/kg to rats pretreated with dexamethasone (a main inducer of CYP3A1/2 in rats), the total areas under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8159 (283 versus 349 microg min/ml) and DA-8164 (98.0 versus 79.8 microg min/ml) were significantly smaller and greater, respectively, than those in control rats.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],79.8,2105,DB06267,Udenafil
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],435,2106,DB06267,Udenafil
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],370,2107,DB06267,Udenafil
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],34.8,2108,DB06267,Udenafil
,15926192,AUC,"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC values of DA-8159 (435 versus 370 microg min/ml) and DA-8164 (34.8 versus 76.5 microg min/ml) were significantly greater and smaller, respectively.","Effects of enzyme inducers and inhibitors on the pharmacokinetics of intravenous DA-8159, a new erectogenic, in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15926192/),[min·μg] / [ml],76.5,2109,DB06267,Udenafil
,20233203,metabolic AUC ratio (AUC(last),"The metabolic AUC ratio (AUC(last) of DA-8164/AUC(last) of udenafil) was 1.71 when udenafil was administered alone, and the value decreased to 0.19 when udenafil was dosed in the presence of ketoconazole.",Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233203/),,1.71,8116,DB06267,Udenafil
,20233203,metabolic AUC ratio (AUC(last),"The metabolic AUC ratio (AUC(last) of DA-8164/AUC(last) of udenafil) was 1.71 when udenafil was administered alone, and the value decreased to 0.19 when udenafil was dosed in the presence of ketoconazole.",Effect of ketoconazole on the pharmacokinetics of udenafil in healthy Korean subjects. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20233203/),,0.19,8117,DB06267,Udenafil
,21881249,flow rate,"Chromatographic separation was performed using Pursuit XRS C₁₈ column (50 mm × 2.1 mm, i.d., 3 μm, Varian Inc., CA, U.S.A.) with an isocratic mobile phase consisting of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) at a flow rate of 0.2 ml/min over a total run time of 2.5 min.",Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21881249/),[ml] / [min],0.2,37191,DB06267,Udenafil
,21881249,total run time,"Chromatographic separation was performed using Pursuit XRS C₁₈ column (50 mm × 2.1 mm, i.d., 3 μm, Varian Inc., CA, U.S.A.) with an isocratic mobile phase consisting of acetonitrile and 10 mM ammonium acetate (90 : 10, v/v) at a flow rate of 0.2 ml/min over a total run time of 2.5 min.",Rapid and sensitive determination of udenafil in plasma by LC-MS/MS for intranasal pharmacokinetic study in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21881249/),min,2.5,37192,DB06267,Udenafil
>,22209996,solubility,Optimized microemulsion formulations with a mean diameter of 120-154 nm achieved enhanced solubility of udenafil (>10mg/ml) compared with its aqueous solubility (0.02 mg/ml).,Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209996/),[mg] / [ml],10,39961,DB06267,Udenafil
,22209996,solubility,Optimized microemulsion formulations with a mean diameter of 120-154 nm achieved enhanced solubility of udenafil (>10mg/ml) compared with its aqueous solubility (0.02 mg/ml).,Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. ,Papp-Q6,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209996/),[mg] / [ml],0.02,39962,DB06267,Udenafil
,22209996,T(max),"According to the results of an in vivo pharmacokinetic study in rats, intranasal administration of udenafil-loaded microemulsion had a shorter T(max) value (1 min) compared with oral administration and improved bioavailability (85.71%) compared with oral and intranasal (solution) administration.",Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209996/),min,1,39963,DB06267,Udenafil
,22209996,bioavailability,"According to the results of an in vivo pharmacokinetic study in rats, intranasal administration of udenafil-loaded microemulsion had a shorter T(max) value (1 min) compared with oral administration and improved bioavailability (85.71%) compared with oral and intranasal (solution) administration.",Development of udenafil-loaded microemulsions for intranasal delivery: in vitro and in vivo evaluations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22209996/),%,85.71,39964,DB06267,Udenafil
,15885460,AUC,"After intravenous administration of DA-8159 at 22:00 h, the AUC of DA-8159 was significantly greater (528 versus 368 microg min/ml) due to significantly slower CL (56.1 versus 79.5 ml/min/kg) in the rats.","Pharmacokinetics of DA-8159, a new erectogenic, administered at 10:00 h versus 22:00 h in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885460/),[min·μg] / [ml],528,42698,DB06267,Udenafil
,15885460,AUC,"After intravenous administration of DA-8159 at 22:00 h, the AUC of DA-8159 was significantly greater (528 versus 368 microg min/ml) due to significantly slower CL (56.1 versus 79.5 ml/min/kg) in the rats.","Pharmacokinetics of DA-8159, a new erectogenic, administered at 10:00 h versus 22:00 h in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885460/),[min·μg] / [ml],368,42699,DB06267,Udenafil
,15885460,CL,"After intravenous administration of DA-8159 at 22:00 h, the AUC of DA-8159 was significantly greater (528 versus 368 microg min/ml) due to significantly slower CL (56.1 versus 79.5 ml/min/kg) in the rats.","Pharmacokinetics of DA-8159, a new erectogenic, administered at 10:00 h versus 22:00 h in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885460/),[ml] / [kg·min],56.1,42700,DB06267,Udenafil
,15885460,CL,"After intravenous administration of DA-8159 at 22:00 h, the AUC of DA-8159 was significantly greater (528 versus 368 microg min/ml) due to significantly slower CL (56.1 versus 79.5 ml/min/kg) in the rats.","Pharmacokinetics of DA-8159, a new erectogenic, administered at 10:00 h versus 22:00 h in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885460/),[ml] / [kg·min],79.5,42701,DB06267,Udenafil
,15885460,AUC,"After intravenous administration of DA-8159 at 22:00 h, the AUC of DA-8164 was also significantly greater (108 versus 66.8 microg min/ml) possibly due to significantly greater exposure of the parent drug (AUC of DA-8159).","Pharmacokinetics of DA-8159, a new erectogenic, administered at 10:00 h versus 22:00 h in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885460/),[min·μg] / [ml],108,42702,DB06267,Udenafil
,15885460,AUC,"After intravenous administration of DA-8159 at 22:00 h, the AUC of DA-8164 was also significantly greater (108 versus 66.8 microg min/ml) possibly due to significantly greater exposure of the parent drug (AUC of DA-8159).","Pharmacokinetics of DA-8159, a new erectogenic, administered at 10:00 h versus 22:00 h in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15885460/),[min·μg] / [ml],66.8,42703,DB06267,Udenafil
,16400709,AUC(0-6 h),"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC(0-6 h) of amlodipine was significantly greater than the controls (34.5+/-6.01 compared with 28.0+/-4.70 microg min/ml), indicating that amlodipine is metabolized via CYP3A1/2 in rats.","Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400709/),[min·μg] / [ml],34.5,43866,DB06267,Udenafil
,16400709,AUC(0-6 h),"In rats pretreated with troleandomycin (a main inhibitor of CYP3A1/2 in rats), the AUC(0-6 h) of amlodipine was significantly greater than the controls (34.5+/-6.01 compared with 28.0+/-4.70 microg min/ml), indicating that amlodipine is metabolized via CYP3A1/2 in rats.","Negligible pharmacokinetic interaction between oral DA-8159, a new erectogenic, and amlodipine in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16400709/),[min·μg] / [ml],28.0,43867,DB06267,Udenafil
,15803515,AUC,"After intravenous administration of DA-8159, the formation of DA-8164 decreased in the order mice, rats, rabbits and dogs; the AUC(DA-8164)/AUC(DA-8159) ratios were 0.479, 0.199, 0.0452 and close to 0 (DA-8164 was below the detection limit in dog plasma), respectively.","Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803515/),,0.479,44740,DB06267,Udenafil
,15803515,AUC,"After intravenous administration of DA-8159, the formation of DA-8164 decreased in the order mice, rats, rabbits and dogs; the AUC(DA-8164)/AUC(DA-8159) ratios were 0.479, 0.199, 0.0452 and close to 0 (DA-8164 was below the detection limit in dog plasma), respectively.","Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803515/),,0.199,44741,DB06267,Udenafil
,15803515,AUC,"After oral administration of DA-8159, the formation of DA-8164 was considerable in mice, rats and humans, but almost negligible in dogs; the AUC (or AUC(0-t))(DA-8164)/AUC (or AUC(0-t))(DA-8159) ratios were 2.99, 2.67, 1.39 and 0.0650, respectively.","Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803515/),,2.99,44742,DB06267,Udenafil
,15803515,AUC,"After oral administration of DA-8159, the formation of DA-8164 was considerable in mice, rats and humans, but almost negligible in dogs; the AUC (or AUC(0-t))(DA-8164)/AUC (or AUC(0-t))(DA-8159) ratios were 2.99, 2.67, 1.39 and 0.0650, respectively.","Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803515/),,2.67,44743,DB06267,Udenafil
,15803515,AUC(0-t),"After oral administration of DA-8159, the formation of DA-8164 was considerable in mice, rats and humans, but almost negligible in dogs; the AUC (or AUC(0-t))(DA-8164)/AUC (or AUC(0-t))(DA-8159) ratios were 2.99, 2.67, 1.39 and 0.0650, respectively.","Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803515/),,2.67,44744,DB06267,Udenafil
,15803515,AUC(0-t),"After oral administration of DA-8159, the formation of DA-8164 was considerable in mice, rats and humans, but almost negligible in dogs; the AUC (or AUC(0-t))(DA-8164)/AUC (or AUC(0-t))(DA-8159) ratios were 2.99, 2.67, 1.39 and 0.0650, respectively.","Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803515/),,1.39,44745,DB06267,Udenafil
,15803515,AUC(0-t),"After oral administration of DA-8159, the formation of DA-8164 was considerable in mice, rats and humans, but almost negligible in dogs; the AUC (or AUC(0-t))(DA-8164)/AUC (or AUC(0-t))(DA-8159) ratios were 2.99, 2.67, 1.39 and 0.0650, respectively.","Species differences in the formation of DA-8164 after intravenous and/or oral administration of DA-8159, a new erectogenic, to mice, rats, rabbits, dogs and humans. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15803515/),,0.06,44746,DB06267,Udenafil
,28577680,maximal concentration,"The 87.5 mg bid cohort was well tolerated, achieved the highest maximal concentration (506 ng/mL) and the highest average concentration over the dosing interval (279 ng/mL), and was associated with a suggestion of improvement in myocardial performance.",Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28577680/),[ng] / [ml],506,44776,DB06267,Udenafil
,28577680,concentration,"The 87.5 mg bid cohort was well tolerated, achieved the highest maximal concentration (506 ng/mL) and the highest average concentration over the dosing interval (279 ng/mL), and was associated with a suggestion of improvement in myocardial performance.",Results of a phase I/II multi-center investigation of udenafil in adolescents after fontan palliation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28577680/),[ng] / [ml],279,44777,DB06267,Udenafil
,11745913,dose-normalized AUC(0-24 h),"For example, after 4-week administration, the dose-normalized AUC(0-24 h) value at 200 mg/kg/day (4.71 and 15.3 microg h/ml) was significantly greater than that at 12.5 mg/kg/day.","Subacute toxicities and toxicokinetics of a new erectogenic, DA-8159, after single and 4-week repeated oral administration in dogs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745913/),[h·μg] / [ml],4.71,69414,DB06267,Udenafil
,11745913,dose-normalized AUC(0-24 h),"For example, after 4-week administration, the dose-normalized AUC(0-24 h) value at 200 mg/kg/day (4.71 and 15.3 microg h/ml) was significantly greater than that at 12.5 mg/kg/day.","Subacute toxicities and toxicokinetics of a new erectogenic, DA-8159, after single and 4-week repeated oral administration in dogs. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11745913/),[h·μg] / [ml],15.3,69415,DB06267,Udenafil
,11913718,total body clearance,"After intravenous administration, DA-8159 was eliminated fast with the mean total body clearance of 126 ml/min/kg, and was almost completely metabolized in rats; 5.98% of intravenous dose of DA-8159 were excreted unchanged in 24-hr urine.","Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913718/),[ml] / [kg·min],126,72770,DB06267,Udenafil
,11913718,absolute oral bioavailibility,The extent of absolute oral bioavailibility of DA-8159 was approximately 25%.,"Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913718/),%,25,72771,DB06267,Udenafil
,11913718,apparent volume of distribution at steady state,"The apparent volume of distribution at steady state was considerably large, 15048 ml/kg, suggesting that DA-8159 has a good affinity to rat tissues.","Pharmacokinetics, stability, and blood partition of DA-8159, a new phosphodiesterase V inhibitor. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11913718/),[ml] / [kg],15048,72772,DB06267,Udenafil
,25483910,t1/2,Udenafil was eliminated with t1/2 = 25 h.,The phosphodiesterase-5-inhibitor udenafil lowers portal pressure in compensated preascitic liver cirrhosis. A dose-finding phase-II-study. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25483910/),h,25,73199,DB06267,Udenafil
,18318773,terminal half-life,"Udenafil reached peak plasma concentrations at 0.8-1.3 h, and then declined mono-exponentially with a terminal half-life of 7.3-12.1 h in the single-dose study.","Safety, tolerability and pharmacokinetics of udenafil, a novel PDE-5 inhibitor, in healthy young Korean subjects. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/18318773/),h,7.3-12.1,96694,DB06267,Udenafil
,15563761,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8164 were significantly smaller after both intravenous (87.0 vs 162 microg min mL(-1)) and oral (144 vs 319 microg min mL(-1)) administration of DA-8159 to PCM rats.,"Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563761/),[min·μg] / [ml],87.0,126773,DB06267,Udenafil
,15563761,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8164 were significantly smaller after both intravenous (87.0 vs 162 microg min mL(-1)) and oral (144 vs 319 microg min mL(-1)) administration of DA-8159 to PCM rats.,"Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563761/),[min·μg] / [ml],162,126774,DB06267,Udenafil
,15563761,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8164 were significantly smaller after both intravenous (87.0 vs 162 microg min mL(-1)) and oral (144 vs 319 microg min mL(-1)) administration of DA-8159 to PCM rats.,"Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563761/),[min·μg] / [ml],144,126775,DB06267,Udenafil
,15563761,total area under the plasma concentration-time curve from time zero to time infinity (AUC),The total area under the plasma concentration-time curve from time zero to time infinity (AUC) values of DA-8164 were significantly smaller after both intravenous (87.0 vs 162 microg min mL(-1)) and oral (144 vs 319 microg min mL(-1)) administration of DA-8159 to PCM rats.,"Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563761/),[min·μg] / [ml],319,126776,DB06267,Udenafil
,15563761,CL(int),This could be supported by significantly slower in-vitro CL(int) (2.04+/-0.646 vs 3.15+/-0.693 microL min(-1) (mg protein)(-1)) for the formation of DA-8164 in hepatic microsomal fraction of PCM rats.,"Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563761/),[μl] / [mg·min],2.04,126777,DB06267,Udenafil
,15563761,CL(int),This could be supported by significantly slower in-vitro CL(int) (2.04+/-0.646 vs 3.15+/-0.693 microL min(-1) (mg protein)(-1)) for the formation of DA-8164 in hepatic microsomal fraction of PCM rats.,"Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563761/),[μl] / [mg·min],3.15,126778,DB06267,Udenafil
,15563761,AUC,"However, after oral administration of DA-8159, the AUC of DA-8159 was significantly greater in PCM rats (194 vs 122 microg min mL(-1)).","Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563761/),[min·μg] / [ml],194,126779,DB06267,Udenafil
,15563761,AUC,"However, after oral administration of DA-8159, the AUC of DA-8159 was significantly greater in PCM rats (194 vs 122 microg min mL(-1)).","Pharmacokinetics of intravenous and oral DA-8159, a new erectogenic, in rats with protein-calorie malnutrition. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15563761/),[min·μg] / [ml],122,126780,DB06267,Udenafil
,14603504,absolute oral bioavailability (F),The extent of absolute oral bioavailability (F) of DA-8159 was 38.0% at a dose of 30 mg/kg.,"Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),%,38.0,143731,DB06267,Udenafil
,14603504,AUCs,"The AUCs were not significantly different between intragastric and intraduodenal administration of DA-8159 at a dose of 30 mg/kg (131 and 127 microg x min/mL), suggesting that gastric first-pass effect of DA-8159 was almost negligible in rats.","Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),[min·μg] / [ml],131,143732,DB06267,Udenafil
,14603504,AUCs,"The AUCs were not significantly different between intragastric and intraduodenal administration of DA-8159 at a dose of 30 mg/kg (131 and 127 microg x min/mL), suggesting that gastric first-pass effect of DA-8159 was almost negligible in rats.","Pharmacokinetics of DA-8159, a new erectogenic, after intravenous and oral administration to rats: hepatic and intestinal first-pass effects. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14603504/),[min·μg] / [ml],127,143733,DB06267,Udenafil
,16259771,total area under the plasma concentration-time curve from time zero to time infinity (AUC(inf)),"After simultaneous intravenous administration, the total area under the plasma concentration-time curve from time zero to time infinity (AUC(inf)) of DA-8159 (746 vs 457 microg min mL(-1)) was found to be significantly greater than with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[min·μg] / [ml],746,171951,DB06267,Udenafil
,16259771,total area under the plasma concentration-time curve from time zero to time infinity (AUC(inf)),"After simultaneous intravenous administration, the total area under the plasma concentration-time curve from time zero to time infinity (AUC(inf)) of DA-8159 (746 vs 457 microg min mL(-1)) was found to be significantly greater than with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[min·μg] / [ml],457,171952,DB06267,Udenafil
,16259771,total body clearance (CL),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],40.2,171953,DB06267,Udenafil
,16259771,total body clearance (CL),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],65.6,171954,DB06267,Udenafil
,16259771,renal clearance (CL(R)),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],1.65,171955,DB06267,Udenafil
,16259771,renal clearance (CL(R)),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],5.11,171956,DB06267,Udenafil
,16259771,nonrenal clearance (CL(NR)),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],38.3,171957,DB06267,Udenafil
,16259771,nonrenal clearance (CL(NR)),"Also, after simultaneous intravenous administration total body clearance (CL) (40.2 vs 65.6 mL min(-1) kg(-1)), renal clearance (CL(R)) (1.65 vs 5.11 mL min(-1) kg(-1)), and nonrenal clearance (CL(NR)) (38.3 vs 60.2 mL min(-1) kg(-1)) of DA-8159 were significantly slower compared with DA-8159 alone.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[ml] / [kg·min],60.2,171958,DB06267,Udenafil
,16259771,AUC(inf),"After the simultaneous intravenous administration of nitroglycerin and DA-8159, the AUC(inf) of nitroglycerin was significantly smaller (635 vs 960 microg min mL(-1)), which could have been due to the cardiac output-dependent CL of nitroglycerin.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[min·μg] / [ml],635,171959,DB06267,Udenafil
,16259771,AUC(inf),"After the simultaneous intravenous administration of nitroglycerin and DA-8159, the AUC(inf) of nitroglycerin was significantly smaller (635 vs 960 microg min mL(-1)), which could have been due to the cardiac output-dependent CL of nitroglycerin.","Pharmacokinetic interaction between 5-[2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl]-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one (DA-8159) and nitroglycerin in rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16259771/),[min·μg] / [ml],960,171960,DB06267,Udenafil
,23390072,flow rate,"Chromatographic separation was performed on a Luna phenyl-hexyl column (100 × 2.0 mm) with an isocratic mobile phase consisting of 5 mM ammonium formate and ACN (23:77, v/v) at a flow rate of 0.35 mL/min.","High-sensitive LC-MS/MS method for the simultaneous determination of mirodenafil and its major metabolite, SK-3541, in human plasma: application to microdose clinical trials of mirodenafil. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23390072/),[ml] / [min],0.35,193377,DB06267,Udenafil
,15295797,AUC,"Intravenous administration of DA-8159, 30 mg/kg, to rats with diabetes mellitus induced by streptozotocin (DMIS), AUC of DA-8164 (a metabolite) was significantly smaller in rats with DMIS (57.9 compared with 81.8 microg x min/mL).","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295797/),[min·μg] / [ml],57.9,193407,DB06267,Udenafil
,15295797,AUC,"Intravenous administration of DA-8159, 30 mg/kg, to rats with diabetes mellitus induced by streptozotocin (DMIS), AUC of DA-8164 (a metabolite) was significantly smaller in rats with DMIS (57.9 compared with 81.8 microg x min/mL).","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295797/),[min·μg] / [ml],81.8,193408,DB06267,Udenafil
,15295797,CL,"For example, the CL of DA-8164 was significantly faster (9.68 compared with 6.29 mL/min/kg) after intravenous administration of DA-8164, 10 mg/kg, to rats with DMIS and in vitro intrinsic clearance for the formation of DA-8164 was significantly faster (1.92 compared with 1.59 microL/min/mg protein) in hepatic microsomal fraction of rats with DMIS due to significant increase in expression of CYP3A1(23) in the rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295797/),[ml] / [kg·min],9.68,193409,DB06267,Udenafil
,15295797,CL,"For example, the CL of DA-8164 was significantly faster (9.68 compared with 6.29 mL/min/kg) after intravenous administration of DA-8164, 10 mg/kg, to rats with DMIS and in vitro intrinsic clearance for the formation of DA-8164 was significantly faster (1.92 compared with 1.59 microL/min/mg protein) in hepatic microsomal fraction of rats with DMIS due to significant increase in expression of CYP3A1(23) in the rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295797/),[ml] / [kg·min],6.29,193410,DB06267,Udenafil
,15295797,intrinsic clearance,"For example, the CL of DA-8164 was significantly faster (9.68 compared with 6.29 mL/min/kg) after intravenous administration of DA-8164, 10 mg/kg, to rats with DMIS and in vitro intrinsic clearance for the formation of DA-8164 was significantly faster (1.92 compared with 1.59 microL/min/mg protein) in hepatic microsomal fraction of rats with DMIS due to significant increase in expression of CYP3A1(23) in the rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295797/),[μl] / [mg·min],1.92,193411,DB06267,Udenafil
,15295797,intrinsic clearance,"For example, the CL of DA-8164 was significantly faster (9.68 compared with 6.29 mL/min/kg) after intravenous administration of DA-8164, 10 mg/kg, to rats with DMIS and in vitro intrinsic clearance for the formation of DA-8164 was significantly faster (1.92 compared with 1.59 microL/min/mg protein) in hepatic microsomal fraction of rats with DMIS due to significant increase in expression of CYP3A1(23) in the rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. ",CLint -Q3,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295797/),[μl] / [mg·min],1.59,193412,DB06267,Udenafil
,15295797,renal clearance,"After intravenous administration of DA-8159, renal clearance was significantly faster in rats with DMIS (5.79 compared with 2.80 mL/min/kg) due to urine flow-dependent renal clearance of DA-8159 in rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295797/),[ml] / [kg·min],5.79,193413,DB06267,Udenafil
,15295797,renal clearance,"After intravenous administration of DA-8159, renal clearance was significantly faster in rats with DMIS (5.79 compared with 2.80 mL/min/kg) due to urine flow-dependent renal clearance of DA-8159 in rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with diabetes mellitus induced by streptozotocin. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15295797/),[ml] / [kg·min],2.80,193414,DB06267,Udenafil
,24817673,m/z,"The analytes were separated in an Atlantis dC18 column using a gradient elution of methanol and 0.1% formic acid, and mass-to-charge ratios were determined in selective reaction monitoring mode using tandem mass spectrometry with m/z 343.12 > 296.97 for homoegonol and m/z 517.30 > 282.90 for udenafil (internal standard).",Quantification of homoegonol in rat plasma using liquid chromatography-tandem mass spectrometry and its pharmacokinetics application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817673/),,343.12,193726,DB06267,Udenafil
>,24817673,m/z,"The analytes were separated in an Atlantis dC18 column using a gradient elution of methanol and 0.1% formic acid, and mass-to-charge ratios were determined in selective reaction monitoring mode using tandem mass spectrometry with m/z 343.12 > 296.97 for homoegonol and m/z 517.30 > 282.90 for udenafil (internal standard).",Quantification of homoegonol in rat plasma using liquid chromatography-tandem mass spectrometry and its pharmacokinetics application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817673/),,296.97,193727,DB06267,Udenafil
,24817673,m/z,"The analytes were separated in an Atlantis dC18 column using a gradient elution of methanol and 0.1% formic acid, and mass-to-charge ratios were determined in selective reaction monitoring mode using tandem mass spectrometry with m/z 343.12 > 296.97 for homoegonol and m/z 517.30 > 282.90 for udenafil (internal standard).",Quantification of homoegonol in rat plasma using liquid chromatography-tandem mass spectrometry and its pharmacokinetics application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817673/),,517.30,193728,DB06267,Udenafil
>,24817673,m/z,"The analytes were separated in an Atlantis dC18 column using a gradient elution of methanol and 0.1% formic acid, and mass-to-charge ratios were determined in selective reaction monitoring mode using tandem mass spectrometry with m/z 343.12 > 296.97 for homoegonol and m/z 517.30 > 282.90 for udenafil (internal standard).",Quantification of homoegonol in rat plasma using liquid chromatography-tandem mass spectrometry and its pharmacokinetics application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817673/),,282.90,193729,DB06267,Udenafil
,24817673,overall recovery,The overall recovery of homoegonol from rat plasma using protein precipitation was 99.7 ± 7.7%.,Quantification of homoegonol in rat plasma using liquid chromatography-tandem mass spectrometry and its pharmacokinetics application. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24817673/),%,99.7,193730,DB06267,Udenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],157,203031,DB06267,Udenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],103,203032,DB06267,Udenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],215,203033,DB06267,Udenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],141,203034,DB06267,Udenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],125,203035,DB06267,Udenafil
,16035131,AUC,"After oral administration of DA-8159 to 16-week-old SHRs, the AUC values of both DA-8159 (157 versus 103 microg min/ml) and DA-8164 (215 versus 141 microg min/ml) were significantly greater, but the values of DA-8159 were reversed in 16-week-old DOCA-salt rats (125 versus 200 microg min/ml).","Pharmacokinetic changes of DA-8159, a new erectogenic, and one of its metabolites, DA-8164 after intravenous and oral administration of DA-8159 to spontaneously hypertensive rats and DOCA-salt-induced hypertensive rats. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16035131/),[min·μg] / [ml],200,203036,DB06267,Udenafil
,15207655,Tmax,"DA-8159 was absorbed rapidly with a Tmax of 0.6 hours in 30 mg/kg and 1.0 hour in the 10 mg/kg group, and T1/2 of 1.23 hours in 30 mg/kg and 1.17 hours in 10 mg/kg, respectively.",DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207655/),h,0.6,218213,DB06267,Udenafil
,15207655,Tmax,"DA-8159 was absorbed rapidly with a Tmax of 0.6 hours in 30 mg/kg and 1.0 hour in the 10 mg/kg group, and T1/2 of 1.23 hours in 30 mg/kg and 1.17 hours in 10 mg/kg, respectively.",DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207655/),h,1.0,218214,DB06267,Udenafil
,15207655,T1/2,"DA-8159 was absorbed rapidly with a Tmax of 0.6 hours in 30 mg/kg and 1.0 hour in the 10 mg/kg group, and T1/2 of 1.23 hours in 30 mg/kg and 1.17 hours in 10 mg/kg, respectively.",DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207655/),h,1.23,218215,DB06267,Udenafil
,15207655,T1/2,"DA-8159 was absorbed rapidly with a Tmax of 0.6 hours in 30 mg/kg and 1.0 hour in the 10 mg/kg group, and T1/2 of 1.23 hours in 30 mg/kg and 1.17 hours in 10 mg/kg, respectively.",DA-8159 has erectile potentials much longer than the plasma half-life in a conscious rabbit model. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15207655/),h,1.17,218216,DB06267,Udenafil
,19660002,t(max),"Under fasting conditions, udenafil was rapidly absorbed and t(max) was observed typically 1.5 h after administration.",Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660002/),h,1.5,218983,DB06267,Udenafil
,19660002,t(max),"The mean t(max) values after a low-fat meal and a high-fat meal were 2.6 and 2.1 h, respectively.",Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660002/),h,2.6,218984,DB06267,Udenafil
,19660002,t(max),"The mean t(max) values after a low-fat meal and a high-fat meal were 2.6 and 2.1 h, respectively.",Effect of food on the pharmacokinetics of the oral phosphodiesterase 5 inhibitor udenafil for the treatment of erectile dysfunction. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19660002/),h,2.1,218985,DB06267,Udenafil
,21458153,time of maximal concentration,The pharmacokinetic profiles of udenafil with a time of maximal concentration of 1.0-1.5h and a terminal half-life of 11-13 h make udenafil a good candidate for once-daily dosing.,"Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21458153/),h,1.0-1.5,219833,DB06267,Udenafil
,21458153,terminal half-life,The pharmacokinetic profiles of udenafil with a time of maximal concentration of 1.0-1.5h and a terminal half-life of 11-13 h make udenafil a good candidate for once-daily dosing.,"Efficacy and safety of once-daily dosing of udenafil in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/21458153/),h,11-13,219834,DB06267,Udenafil
,14689469,AUC(0-24 h),"After a single oral administration, the dose-normalized area under the plasma concentration-time curve from time zero to the last measured time, 24 h, in plasma (AUC(0-24 h)) was significantly different among the three doses (the AUC(0-24 h) based on 20 mg/kg/day was 2.33, 7.00 and 4.19 microg h/ml for 20, 80 and 320 mg/kg/day, respectively).","Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14689469/),[h·μg] / [ml],2.33,225650,DB06267,Udenafil
,14689469,AUC(0-24 h),"After a single oral administration, the dose-normalized area under the plasma concentration-time curve from time zero to the last measured time, 24 h, in plasma (AUC(0-24 h)) was significantly different among the three doses (the AUC(0-24 h) based on 20 mg/kg/day was 2.33, 7.00 and 4.19 microg h/ml for 20, 80 and 320 mg/kg/day, respectively).","Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14689469/),[h·μg] / [ml],7.00,225651,DB06267,Udenafil
,14689469,AUC(0-24 h),"After a single oral administration, the dose-normalized area under the plasma concentration-time curve from time zero to the last measured time, 24 h, in plasma (AUC(0-24 h)) was significantly different among the three doses (the AUC(0-24 h) based on 20 mg/kg/day was 2.33, 7.00 and 4.19 microg h/ml for 20, 80 and 320 mg/kg/day, respectively).","Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14689469/),[h·μg] / [ml],4.19,225652,DB06267,Udenafil
,14689469,AUC(0-24 h),"Similar results were also obtained from DA-8164, a metabolite of DA-8159; the AUC(0-24 h) of DA-8164 after dose-normalized to 20 mg/kg/day of DA-8159 were 2.74, 5.00 and 1.68 microg h/ml, respectively.","Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14689469/),[h·μg] / [ml],2.74,225653,DB06267,Udenafil
,14689469,AUC(0-24 h),"Similar results were also obtained from DA-8164, a metabolite of DA-8159; the AUC(0-24 h) of DA-8164 after dose-normalized to 20 mg/kg/day of DA-8159 were 2.74, 5.00 and 1.68 microg h/ml, respectively.","Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14689469/),[h·μg] / [ml],5.00,225654,DB06267,Udenafil
,14689469,AUC(0-24 h),"Similar results were also obtained from DA-8164, a metabolite of DA-8159; the AUC(0-24 h) of DA-8164 after dose-normalized to 20 mg/kg/day of DA-8159 were 2.74, 5.00 and 1.68 microg h/ml, respectively.","Subacute toxicities and toxicokinetics of DA-8159, a new phosphodiesterase type V inhibitor, after single and 4-week repeated oral administration in rats. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14689469/),[h·μg] / [ml],1.68,225655,DB06267,Udenafil
,15083502,area under the plasma concentration-time curve from time zero to time infinity (AUC),This resulted in a significantly greater area under the plasma concentration-time curve from time zero to time infinity (AUC) of DA-8159 in rats with U-ARF (304 compared with 365 microg min/ml for control rats and rats with U-ARF).,"Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[min·μg] / [ml],304,249074,DB06267,Udenafil
,15083502,area under the plasma concentration-time curve from time zero to time infinity (AUC),This resulted in a significantly greater area under the plasma concentration-time curve from time zero to time infinity (AUC) of DA-8159 in rats with U-ARF (304 compared with 365 microg min/ml for control rats and rats with U-ARF).,"Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[min·μg] / [ml],365,249075,DB06267,Udenafil
,15083502,total body clearance (Cl),The significantly greater AUC in rats with U-ARF was due to significantly slower total body clearance (Cl) of DA-8159 (98.6 compared with 82.2 ml/min/kg).,"Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[ml] / [kg·min],98.6,249076,DB06267,Udenafil
,15083502,total body clearance (Cl),The significantly greater AUC in rats with U-ARF was due to significantly slower total body clearance (Cl) of DA-8159 (98.6 compared with 82.2 ml/min/kg).,"Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[ml] / [kg·min],82.2,249077,DB06267,Udenafil
,15083502,renal clearance,"The significantly slower Cl in rats with U-ARF was due to slower renal clearance (1.07 ml/min/kg compared with not calculable, due to impaired kidney function) and nonrenal clearance (97.5 compared with 82.2 ml/min/kg due to slower metabolism) than those in control rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",CLR-Q26,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[ml] / [kg·min],1.07,249078,DB06267,Udenafil
,15083502,nonrenal clearance,"The significantly slower Cl in rats with U-ARF was due to slower renal clearance (1.07 ml/min/kg compared with not calculable, due to impaired kidney function) and nonrenal clearance (97.5 compared with 82.2 ml/min/kg due to slower metabolism) than those in control rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[ml] / [kg·min],97.5,249079,DB06267,Udenafil
,15083502,nonrenal clearance,"The significantly slower Cl in rats with U-ARF was due to slower renal clearance (1.07 ml/min/kg compared with not calculable, due to impaired kidney function) and nonrenal clearance (97.5 compared with 82.2 ml/min/kg due to slower metabolism) than those in control rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[ml] / [kg·min],82.2,249080,DB06267,Udenafil
,15083502,AUC,"After oral administration of DA-8159 to rats with U-ARF, the AUC (122 compared with 172 microg min/ml) was significantly greater and Cl(R) was slower (3.47 ml/min/kg compared with not calculable) than those in control rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[min·μg] / [ml],122,249081,DB06267,Udenafil
,15083502,AUC,"After oral administration of DA-8159 to rats with U-ARF, the AUC (122 compared with 172 microg min/ml) was significantly greater and Cl(R) was slower (3.47 ml/min/kg compared with not calculable) than those in control rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[min·μg] / [ml],172,249082,DB06267,Udenafil
,15083502,Cl(R),"After oral administration of DA-8159 to rats with U-ARF, the AUC (122 compared with 172 microg min/ml) was significantly greater and Cl(R) was slower (3.47 ml/min/kg compared with not calculable) than those in control rats.","Pharmacokinetic changes of DA-8159, a new erectogenic, after intravenous and oral administration to rats with acute renal failure induced by uranyl nitrate. ",CL ratio-Q31,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15083502/),[ml] / [kg·min],3.47,249083,DB06267,Udenafil
,27006150,Cmax,"The mean Cmax of udenafil tended to be slightly less (214.0 vs 292.8 μg/L) in the elderly compared with the young (GMR, 68.9; 95% CI, 48.9-97.1); however, the AUC did not differ between the groups (1858.8 vs 2100.6 μg·h/L; GMR, 84.6; 95% CI, 66.1-108.4).",The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006150/),[μg] / [l],214.0,249109,DB06267,Udenafil
,27006150,Cmax,"The mean Cmax of udenafil tended to be slightly less (214.0 vs 292.8 μg/L) in the elderly compared with the young (GMR, 68.9; 95% CI, 48.9-97.1); however, the AUC did not differ between the groups (1858.8 vs 2100.6 μg·h/L; GMR, 84.6; 95% CI, 66.1-108.4).",The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006150/),[μg] / [l],292.8,249110,DB06267,Udenafil
,27006150,AUC,"The mean Cmax of udenafil tended to be slightly less (214.0 vs 292.8 μg/L) in the elderly compared with the young (GMR, 68.9; 95% CI, 48.9-97.1); however, the AUC did not differ between the groups (1858.8 vs 2100.6 μg·h/L; GMR, 84.6; 95% CI, 66.1-108.4).",The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006150/),[h·μg] / [l],1858.8,249111,DB06267,Udenafil
,27006150,AUC,"The mean Cmax of udenafil tended to be slightly less (214.0 vs 292.8 μg/L) in the elderly compared with the young (GMR, 68.9; 95% CI, 48.9-97.1); however, the AUC did not differ between the groups (1858.8 vs 2100.6 μg·h/L; GMR, 84.6; 95% CI, 66.1-108.4).",The Effect of Age on the Pharmacokinetics of Udenafil in Healthy Subjects. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27006150/),[h·μg] / [l],2100.6,249112,DB06267,Udenafil
,14522022,flow rate,"A Capcell Pak C18 UG120 column (150 mm x 4.6 mm I.D., 5 microm) was used as a stationary phase and the mobile phase consisted of 30% acetonitrile and 70% 20mM potassium phosphate buffer (pH 4.5) at a flow rate of 1.0 ml/min.","Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522022/),[ml] / [min],1.0,260966,DB06267,Udenafil
greater,14522022,recovery,The recovery of DA from human plasma and urine was greater than 70%.,"Sensitive liquid chromatography assay with ultraviolet detection for a new phosphodiesterase V inhibitor, DA-8159, in human plasma and urine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14522022/),%,70,260967,DB06267,Udenafil
